E74-like factor inhibition induces reacquisition of hormone sensitiveness decreasing period circadian protein homolog 1 expression in prostate cancer cells  by Koyama, Kohei et al.
lable at ScienceDirect
Prostate International 3 (2015) 16e21Contents lists avaiProstate International
journal homepage: http: / /p- internat ional .orgE74-like factor inhibition induces reacquisition of hormone
sensitiveness decreasing period circadian protein homolog
1 expression in prostate cancer cells*
Kohei Koyama, Kiyoshi Takahara*, Teruo Inamoto, Naokazu Ibuki, Koichiro Minami,
Hirofumi Uehara, Kazumasa Komura, Takeshi Nishida, Takeshi Sakamoto, Hajime Hirano,
Hayahito Nomi, Satoshi Kiyama, Haruhito Azuma
Department of Urology, Faculty of Medicine, Osaka Medical College, Osaka, Japana r t i c l e i n f o
Article history:
Received 22 November 2014
Accepted 27 December 2014
Available online 10 March 2015
Keywords:
Castrate-resistant disease
Prostate cancer* Kohei Koyama, Kiyoshi Takahara, and Teruo Inamo
work.
* Corresponding author. Department of Urology,
Daigaku-cho, Takatsuki, Osaka, 569-8686, Japan.
E-mail address: uro037@poh.osaka-med.ac.jp (K. T
http://dx.doi.org/10.1016/j.prnil.2015.02.004
p2287-8882 e2287-903X/© 2015 Published by Elsev
creativecommons.org/licenses/by-nc-nd/4.0/).a b s t r a c t
Purpose: Initiating as an androgen-dependent adenocarcinoma, prostate cancer (PCa) gradually pro-
gresses to a castrate-resistant disease following androgen deprivation therapy with a propensity to
metastasize.
Methods: In order to resolve the mechanism of castrate-resistant PCa, we performed a cDNA-microarray
assay of two PCa cell lines, LNCaP (androgen dependent) and C4-2 (androgen independent). Among
them, we focused on a novel Ets transcription factor, E74-like factor 5 (ELF5), the expression level of
which was extremely high in C4-2 in comparison with LNCaP both in the microarray analysis and real-
time polymerase chain reaction analysis, and investigated the biological role in acquisition of androgen-
refractory PCa growth.
Results: Western blot analysis and morphological analysis using confocal immunoﬂuorescence micro-
scopy demonstrated that ELF5 was expressed mainly in cytosol both in LNCaP and C4-2. Inhibition of
ELF5 expression using ELF5-small interfering RNA in C4-2 induced decreased expression of androgen
receptor corepressor, period circadian protein homolog 1, and MTT assay of C4-2 after ELF5 small
interfering RNA transfection showed the same cell growth pattern of LNCaP.
Conclusions: Our in vitro experiments of cell growth and microarray analysis have demonstrated for the
ﬁrst time that decreased expression of period circadian protein homolog 1 due to ELF5 inhibition may
induce the possibility of reacquisition of hormone sensitiveness of PCa cells. We suggest that ELF5 could
be a novel potential target for the treatment of hormone-refractory PCa patients.
© 2015 Published by Elsevier B.V. on behalf of Prostate International. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Ets family of transcription factors share a highly conserved
DNA binding domain, termed the Ets domain, ﬁrst identiﬁed in the
gag-myb-ets fusion protein of avian leukemia virus E26.1 Although
Ets family members bind to a similar core DNA recognition
sequence, GGAA/T, the differences in the sequences ﬂanking the
core appear to contribute towards Ets factor binding speciﬁcity and,to contributed equally to this
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akahara).
ier B.V. on behalf of Prostate Intehence, function.2,3 Ets genes encode a family of transcription factors
that regulate a spectrum of normal biological activities including
development, differentiation, homeostasis, proliferation, and
apoptosis. The family consists of 27 members in humans with
expression in a variety of tissues; however, most Ets transcription
factors are expressed either ubiquitously or restricted to hemo-
poietic cells. In hemopoietic cells, Ets genes such as the archetypal
family member, Ets-1, are crucial for maintaining a normal differ-
entiated cell phenotype. Ets factors integrate extracellular signals at
the transcriptional level, resulting in the activation of a large set of
target genes.4
Prostate-derived Ets factor (PDEF), also known as sterile amotif-
pointed domain containing Ets transcription factor is a relatively
novel member of the Ets family of transcription factors. In contrast
to normal tissues where the limited tissue-speciﬁc expression ofrnational. This is an open access article under the CC BY-NC-ND license (http://
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still under investigation. Herein, to investigate the role of Ets family
in PCa, we conducted the present study to examine alterations in
the PDEF gene expression patterns in C4-2, an androgen-
independent PCa cell line, in comparison with LNCaP, an
androgen-dependent PCa cell line. We focused on the ELF5 gene,
E74-like factor 5, whose expression was much higher in C4-2 than
in LNCaP both in the microarray analysis and real-time polymerase
chain reaction (PCR) analysis.
The transcriptional regulator E74-like factor 5 (ELF5) has pre-
viously been associated with regulation of placentation and
alveologenesis, the process by which the mammary gland develops
milk-producing acinar structures during pregnancy.5e7 Unlike most
other Ets family members,8,9 ELF5 is not expressed in hematopoi-
etic compartments, but is restricted to organs such as lung, stom-
ach, kidney, prostate, bladder, and mammary gland. Xie et al.10
demonstrated that functional evaluation revealed ELF5/ESE-2b
expressions contributed to the malignant phenotypes of PCa
cells; however, the role of ELF5 in PCa is still unclear.
Our in vitro experiments of cell growth and microarray analysis
have demonstrated for the ﬁrst time that decreased expression of
period circadian protein homolog 1 (PER1) due to ELF5 inhibition
may induce the possibility of reacquisition of hormone sensitive-
ness of PCa cells. Further investigations should be pursued, and we
suggest that ELF5 could be a novel potential target for the treat-
ment of hormone-refractory PCa patients.
2. Methods
2.1. Cell lines
Human PCa cell line LNCaP was purchased from the American
Type Culture Collection (Rockville, MD, USA). Human PCa cell line
C4-2 was obtained from Dr L.W. Chung (University of Virginia,
Charlottesville, VA, USA). Both cells were maintained in RPMI1640
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin (Life Technologies, Burlington, ON, Canada) at 37 C in
a humidiﬁed atmosphere containing 5% CO2.
2.2. RNA isolation and quality measurement
Total RNA of LNCaP or C4-2 was isolated with TRIzol reagent
(Life Technologies) in accordance with the manufacturer's in-
structions. The quality of the RNAwas veriﬁed with an Agilent 2100
bio-analyzer (Agilent Technologies, Palo Alto, CA, USA).
2.3. Microarray analysis and data acquisition
A cDNA microarray containing a set of 17,086 sequence-veriﬁed
human cDNA clones (Life Technologies) was provided by Genomic
Tree, Inc. (Daejon, Seaol, South Korea). The synthesis of target cDNA
and hybridization were performed in accordance with the manu-
facturer's protocol. Microarray scanning was performed using a
GenePix 4000B (Molecular Devices Corporation, Sunnyvale, CA,
USA) and analyzed using GenePix Pro6.0 (Molecular Devices). All
data normalization and selection were performed using Gene
Spring 7.3 (Agilent Technologies).
2.4. Real-time polymerase chain reaction analysis
Reverse transcription was carried out with TaqMan RT kit
(Applied Biosystems, Foster City, CA, USA) according to the manu-
facturer's instructions. Brieﬂy, it was used in a volume of 100 mL
with 300 ng RNA sample, 15 pmol of oligo deoxythymidine primer
and random primer, 10 mL of 10 TaqMan Buffer, 22 mL of 25 mMMgCl2, 20 mL of each 2.5 mM dNTP mix, RNase inhibitor, reverse
transcriptase. RTconditions were following: 10min at 25 C, 30min
at 45 C, 5 min at 95 C. Real-time polymerase chain reaction was
performed in an ABI PRISM 7900HT machine (Applied Biosystems)
using SYBR Green PCR Master Mix (Applied Biosystems) according
to the manufacturer's instructions in a total volume 25 mL. Cycling
conditions were: 2 min at 50 C, 10 min at 94 C, 40 cycles of 15 s at
94 C, 30 s at 58 C, 1 min at 60 C. To correlate the threshold (Ct)
values from the ampliﬁcation plots to copy number, a standard
curve was generated and nontemplate control was run with every
assay. Normalized expression quantity of mRNA was calculated as:
Mean of each gene expression quantity/Mean of GAPDH expression
quantity  1000.
2.5. Confocal immunoﬂuorescence microscopy
Immunoﬂuorescence examination of ELF5 was performed in
LNCaP and C4-2. Both PCa lines were seeded at 5  104 cells in
eight-well chamber slides with a collagen coat (BD Biosciences, San
Jose, CA, USA) in RPMI1640 medium supplemented with 10% FBS,
100 units/mL penicillin and 100 mg/mL streptomycin. The primary
antibody used was anti-ELF5 goat polyclonal antibody (Abcam,
Cambridge, UK) and the secondary antibody was Alexa Fluor 488
anti-goat IgG (Molecular Probes, Eugene, OR, USA). Nuclei were
stained with PI solution (Dojindo, Kumamoto, Japan). Cells were
visualized on an Olympus Fluoview FV500 confocal laser scanning
microscope (Olympus, Tokyo, Japan).
2.6. Subcellular fractionation and immunoblotting
Puriﬁed proteins from four subcellular fractions of LNCaP and
C4-2dorganelle, cytosolic, cytoskeletal, and nucleic frac-
tionsdwere obtained using a ProteoExtract Subcellular Proteome
Extraction Kit (Merck, Darmstadt, Germany) according to the
manufacturer's instructions. Brieﬂy, 5 mg of protein obtained from
each subcellular fraction was loaded and separated using 15% so-
dium dodecyl sulfate-polyacrylamide gel (Bio Craft, Tokyo, Japan)
electrophoresis, and then electroblotted onto Immobilon-P poly-
vinylidene diﬂuoride membrane (Millipore, Billerica, MA, USA).
Immunoblotting was performed with the primary antibodies: anti-
ELF5 rabbit polyclonal antibody (Abcam). Immunoblots were
exposed to the secondary antibody, anti-rabbit IgG HRP-linked
whole antibody, and visualized using ECL Plus chem-
iluminescence detection reagents (GE Healthcare, Uppsala,
Sweden).
2.7. Small interfering RNA transfection in C4-2 (real-time PCR)
Human prostate cancer C4-2 cells were grown in RPMI1640
medium supplemented with 10% FBS, 100 units/mL penicillin, and
100 mg/mL streptomycin. Chemically synthesized ELF5 small
interfering (si)RNA and negative control siRNA (B-bridge Interna-
tional, Mountain View, CA, USA; Supplemental Data 1) were diluted
in 100 mL RPMI1640 without serum in the wells of a tissue culture
six-well plate and mixed gently. Lipofectamine RNAiMAX (4 mL;
Invitrogen) was added to each well containing the diluted RNA
interference molecules, mixed gently and incubated for 10e20 min
at room temperature. The cells (70e90% conﬂuence) were detached
by trypsin-EDTA treatment, resuspended in RPMI1640 without
antibiotics, and plated into a six-well plate at a density of 4  105
cells for 1-day transfection, 2  105 cells for 2-day transfection, and
1  105 cells for 3-day transfection/3 mL/well containing RNA
interference molecules and Lipofectamine mixture. After 24e72 h
of incubation, the cells were harvested for real-time RT-PCR anal-
ysis of the knockdown level of the exogenous mRNA by siRNA. For
Fig. 1. Real-time polymerase chain reaction analysis of Ets transcription factors (LNCaP
vs. C4-2).
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transfected with the same concentration of negative siRNA control.
2.8. Cell growth assay
C4-2, and C4-2 treated with ELF5 siRNA or negative control
siRNAwere seeded in eachwell of 96-well plates andmaintained in
RPMI1640 medium supplemented with 10% FBS, 100 units/mL
penicillin and 100 mg/mL streptomycin or RPMI1640 medium
supplemented with 10% charcoal/dextran-treated FBS (Thermo
Scientiﬁc, Waltham, MA, USA), 100 units/mL penicillin and 100 mg/
mL streptomycin. Transfections were performed with a mixture of
siRNA and Lipofectamine RNAiMAX transfection reagent. The ﬁnal
concentrations of siRNA and Lipofectamine RNAiMAX used in each
transfection were 10 nM and 0.12 mL per well, respectively. Cells
were cultured for 1 day, 2 days, and 3 days at 37 C in a humidiﬁed
atmosphere containing 5% CO2. Each time-course screening assay
was performed using triplicate cultures for three independent
experiments.
2.9. siRNA transfection in C4-2 (microarray analysis)
ELF5 siRNA and negative control siRNAwere diluted in 500 mL of
serum-free RPMI1640 in one well of a six-well tissue culture plate
and mix gently. Lipofectamine RNAiMAX (4 mL) was added to each
well containing 30 pmol siRNA and incubated for 20 min at room
temperature. The cells (at 70e90% conﬂuence) were detached us-
ing trypsin-EDTA, re-suspended in RPMI1640 without antibiotics,
and 2 105 cells were plated in a volume of 3 mL into each well of a
six-well plate for 2-day transfection with siRNA and the Lipofect-
amine RNAiMAX mixture. After 48 h of incubation at 37 C in a
humidiﬁed atmosphere containing 5% CO2, the cells were harvested
for microarray analysis. For targeting and detection of the endog-
enous gene level, cells were transfected with the same concentra-
tion of negative control siRNA.
2.10. Statistical analysis
The unpaired Student t test was applied to values obtained by
in vitro experiments. Differences at P < 0.05 were considered to be
statistically signiﬁcant.
3. Results
3.1. cDNA microarray analysis of the hormone-refractory PCa cell
line C4-2 and the hormone-sensitive PCa cell line LNCaP
cDNA microarray analysis with a set of 17,086 sequence-veriﬁed
human cDNA clones was performed on the hormone-refractory PCa
cell line C4-2 and the hormone-sensitive PCa cell line LNCaP. In the
PCa-related genes, we focused on Ets transcription factors (ELF5,
ELF3, EHF, and SPDEF), presented as expression values in Table 1.
Among them, there were less than two-fold differences of gene
expression levels of ELF3, EHF, and SPDEF between LNCaP and C4-2.Table 1
cDNA microarray aanalysis in LNCaP and C4-2 cells.
Expression ratio
(C4-2/LNCaP)
Gene expression normalized to GAPDH Gene symb
LNCaP C4-2
19.52 594.96 11613 ELF5
0.69 2773.91 1925 ELF3
1.39 14813.51 20609 EHF
1.56 1152.71 1801 SPDEFBy contrast, the ELF5 gene, E74-like factor 5, was more highly
expressed in C4-2 than in LNCaP (11,613 vs. 594.96) and the ratio of
C4-2 expressing ELF5 relative to LNCaP was >19-fold (19.52).
3.2. mRNA quantiﬁcation of Ets transcription factors using real-
time PCR
We next evaluated mRNA levels of ELF5, ELF3, EHF, and SPDEF
using real-time PCR analysis. There were less than two-fold dif-
ferences of mRNA levels of ELF3, EHF, and SPDEF between LNCaP
and C4-2, while, consistent with microarray analysis, mRNA of ELF5
in C4-2 was more highly expressed as compared with LNCaP
(423.289 vs. 42.272), and the ratio of C4-2 expressing ELF5 mRNA
relative to LNCaP was >10-fold (10.01; Fig. 1). Herein, among these
Ets transcription factors, we focused on ELF5, whose expression
was much higher in C4-2 than in LNCaP, and investigated its
biochemical or biological role in the acquisition of androgen-
independent growth of C4-2.
3.3. Localization of ELF5 expression
Next we examined the localization of ELF5 expression in LNCaP
and C4-2 using western blot analysis. We performed western blot
analysis on fractions of cytosol, organelles, nucleus, and cytoskel-
eton separated from each cell line using a ProteoExtract Subcellular
Proteome Extraction Kit. ELF5 expression was mainly in cytosol in
both LNCaP and C4-2 (Fig. 2A). Then we evaluated the ELF5
expression in cytosol using confocal immunoﬂuorescence micro-
scopy. Consistent with the data obtained by western blot analysis,
the microscopy demonstrated ELF5 was expressed mainly in
cytosol in both cell lines, however, there was no signiﬁcant differ-
ence in the pattern of ELF5 expression between LNCaP and C4-2
(Fig. 2B).ol Genebank ID Gene name
NM_001422 E74-Iike factor 5 (ets domain transcription factor)
NM_004433 E74-Iike factor 3 (ets domain transcription factor)
NM_012153 ESE3 transcription factor
NM_012391 Prostate epithelium-speciﬁc Ets transcription factor
Fig. 2. Representative pictures of (A) western blot analysis and (B) confocal immunoﬂuorescence microscopy in LNCaP and C4-2.
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In order to investigate the inﬂuence of ELF5 expression on PCa
cells, we next transfected chemically synthesized ELF5 siRNA into
C4-2 cells. Real-time PCR analysis was used to determine speciﬁcity
and potency of ELF5 siRNA on inhibiting ELF5 mRNA levels of C4-2
cells as comparedwith negative control RNA. After the treatment of
ELF5 siRNA on C4-2, ELF5 mRNA levels of C4-2 was stablyFig. 3. Real-time polymerase chain reaction analysis after the transfection of chemi-
cally synthesized ELF5 siRNA and negative control RNA on C4-2.suppressed at 1 day, 2 days, and 3 days as compared with the
treatment of negative control (siRNA/negative control RNA ratio: 1
day 18.2%, 2 days 12.4%, 3 days 13.7%; Fig. 3).
3.5. Acquisition of androgen-dependent cell growth due to ELF5
inhibition in C4-2
We next examined the inﬂuence of ELF5 inhibition on cell
growth using an MTT assay. In medium containing 10% FBS or 10%Fig. 4. MTT assay expressed as the growth ratio calculated with values of Day 3/Day 1.
Table 2
cDNA microarray aanalysis in C4-2 cells.
Expression ratio
(Neg 10 nM/siRNA 10 nM)
Gene expression normalized to GAPDH Gene symbol Genebank ID Gene name
Negative 10 nM siRNA 10 nM
0.5 204.3 411.9 PER1 NM_002616 Period homolog 1 (Drosophila)
0.25 374.56 1488.1 ELF5 NM_001422 E74-Iike factor 5 (ets domain transcription factor)
K. Koyama et al. / Prostate International 3 (2015) 16e2120androgen-depleted serum, the C4-2 growth ratio (Day 3/Day 1) after
the treatment of ELF5 siRNA or negative control transfection was
compared with those of no treatment. In normal medium, the MTT
assay demonstrated that therewere no signiﬁcant differences of C4-
2 growth ratio between the treatment of ELF5 siRNA or negative
control transfection and that of no treatment. By contrast, in me-
diumwith androgen-depleted serum, the C4-2 growth ratiowas not
affected after the treatment of ELF5 negative control transfection,
while C4-2 growth ratio after the treatment of ELF5 siRNA trans-
fection was signiﬁcantly decreased as compared with that of no
treatment (Fig. 4). These results indicated that the treatment of ELF5
inhibition may induce the possibility of re-acquisition of hormone
sensitiveness in hormone-refractory PCa cells.
3.6. Changes in pattern of gene expression due to ELF5 inhibition by
siRNA-ELF5 transfection in C4-2 cells: decreased expression of
androgen receptor corepressor, PER1
We next investigated the inﬂuence of ELF5 expression on the
expression pattern of other genes. We transfected chemically syn-
thesized ELF5 siRNA into C4-2 cells, and investigated the changes in
the pattern of gene expression using cDNA array analysis. Among
the two-fold-changed genes reported in Supplemental Data 2, we
found decreased expression of androgen receptor (AR) corepressor,
PER1 in C4-2 after ELF5 inhibition as compared with C4-2 with
negative control transfection (Table 2). These results indicate that
decreased expression of PER1 due to ELF5 inhibition may induce
the possibility of re-acquisition of hormone sensitiveness in
hormone-refractory PCa cells, suggesting a promising avenue of
treatment for hormone-refractory PCa patients.
4. Discussion
Recurrent chromosomal rearrangements are key to develop-
ment of many hematologic malignancies and sarcomas. PDEF,
known as one of relatively novel Ets transcription factors, was
originally reported to show strong expression in normal human
prostate tissue with weak expression in normal breast and ovary.11
In PCa, some groups have reported loss of PDEF during tumor
progression,12,13 whereas others showed increased expression of
PDEF in PCa in comparisonwith benign and prostate intraepithelial
neoplasia (a premalignant lesion) tissues.14 PDEF expression is
induced via signaling through the AR,14,15 and it is well-recognized
that signaling through AR remains active in castration-resistant
advanced PCa.16
In the present study, we focused on another novel Ets tran-
scription factor, ELF5, whose expression level was extremely high in
C4-2, an androgen-independent PCa cell line, in comparison with
LNCaP, an androgen-dependent PCa cell line, both in microarray
analysis and real-time PCR analysis. ELF5, also known as ESE217 is a
member of the epithelium speciﬁc subgroup of the large Ets tran-
scription factor family.18 As mentioned above, ELF5 is found in lung,
placenta, kidney, and most prominently in the breast especially
during pregnancy and lactation2,19,20; however, the mechanism and
role in PCa still under investigation. ELF5 was expressed mainly in
cytosol in both cell lines, LNCaP and C4-2. There was no signiﬁcantdifference in the pattern of ELF5 expression between LNCaP and C4-
2. In order to resolve the mechanism of ELF5 in hormone-
independent environment, we transfected chemically synthesized
ELF5 siRNA into C4-2 cells, and investigated cell growth using MTT
assay. MTT assay of androgen-independent PCa cell line, C4-2 after
ELF5 siRNA transfection demonstrated the same cell growth
pattern of androgen-dependent PCa cell line, LNCaP. This cell
growth experiment indicated that the treatment of ELF5 inhibition
may induce the possibility of re-acquisition of hormone sensitive-
ness in hormone-refractory PCa cells. We then investigated the
inﬂuence of ELF5 on the expression patterns of other genes in cDNA
microarray analysis after ELF5 inhibition in C4-2 cells. We found
decreased expression of androgen receptor corepressor, PER1, in
C4-2 after ELF5 inhibition as compared with C4-2 with negative
control transfection.
PER1 is a protein that is encoded in humans by the Per1 gene.21
Circadian rhythms are driven by a master clock located in the hy-
pothalamic suprachiasmatic nucleus that synchronizes numerous
subsidiary oscillators in peripheral tissues. The circadian clockwork
in both the suprachiasmatic nucleus and the peripheral cells is
regulated by ﬁnely tuned transcriptionetranslation feedback loops
and post-translational modiﬁcations that are maintained by a core
set of clock genes.22e25 The positive feedback loop involves two
transcription factors, Clock and Bmal1, which dimerize and bind to
E-boxes in the promoters of a large number of target genes. These
include their own negative regulators period (PER1, PER2, and
PER3) and cryptochrome (Cry1 and Cry2). Circadian rhythms in-
ﬂuence many physiologic processes and pathologic conditions
including cancer.26,27 PER1 and PER2 have been reported to be
deregulated in several human cancers.28 In PCa, Cao et al.29 suggest
that activated AR stimulates PER1, which in turn attenuates AR
activity, and investigate the connections between clock genes and
the AR pathway could beneﬁt the development of new therapeutic
strategies for PCa patients.
In our experiments, the expression level of AR in microarray
analysis was not affected after ELF5 inhibition in C4-2 cells
(Supplemental Data 2: AR <2-fold-changed genes); however,
decreased expression of PER1 inﬂuenced the mechanism of AR,
then AR may occur characteristic conversion from a hormone-
independent to hormone-dependent state.
In conclusion, our in vitro experiments have demonstrated for
the ﬁrst time that decreased expression of PER1 due to ELF5 inhi-
bition may induce the possibility of re-acquisition of hormone
sensitiveness in hormone-refractory PCa cells. Our in vitro data
regarding re-acquisition of hormone sensitiveness on hormone
independent PCa appear to have important implications for future
research on PCa.
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Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.prnil.2015.02.004.
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